Find in Library

Sorafenib was approved in 2005 for the treatment of metastatic renal cell carcinoma and advanced hepatocellular carcinoma (HCC). Acute pancreatitis is a side-effect of sorafenib usage. We present a patient with advanced HCC who presented with acute Grade D pancreatitis caused by sorafenib administration. Following the discontinuation of sorafenib, fasting, and fluid replacement, the patient′s clinical manifestation of Grade D pancreatitis subsided in a short time. One month after discharge, she resumed sorafenib treatment (200 mg/day) due to disease progression. Based on this experience, resumption of sorafenib treatment appears to be safe.